WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended September 30, 2023. “Building on the momentum generated in the first half of 2023,…Read More
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
